Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q4 2016 Earnings Presentation
10 slides from Agilent Technologies's earnings presentation, 2016
Slide 1: Agilent Technologies Q4'16 Results Presentation
Agilent Technologies Q4'16 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company’s goals, priorities, revenues, operating profit and operating margin, growth opportunities, customer service and innovation plans, new product introduction
Slide 3: Agilent Results Q4'16
Agilent Results Q4'16 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q4'16 Financial Metrics Q4'16 and FY16 Headlines • Revenues: $1.11B, +6.3% y/y core(1)(2),+7.3% • FY16 Core growth(1)(2) finished at +5.9%, +4.1% reported (+0.4% FX, +0.6% M&A/NMR). Robust rep
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) Instrumentation and Informatics • Mixed core revenue growth across regions for Analytical Laboratories with strength in Asia. Pharma, Food and Forensics strength partially offset by ongoing softness in Chemical & Energy. Momentum in LC, LC/MS, and ICP/MS
Slide 5: Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) • Continued momentum, growth led by Analytical Laboratory Consumables and Services Pharma and Food, continued expansion in Asia, and strength in LC Columns, Lab Supplies, and Contract Services. • Operating Margin in the quarter was in-line with expectations at 22.7%(1)(
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) Pathology, Genomics, and • Mixed growth across businesses led by Nucleic Acid Manufacturing Diagnostics and Nucleic Acid Solutions. Regional strength in Asia and Europe. • Operating Margin for the quarter was 19.6%(1)(2), up 40 bps versus last year. NGS Target En
Slide 7: Growth in a $47B Market – Q4'16 Results by End Market
Growth in a $47B Market – Q4'16 Results by End Market Solid core growth led again by Pharma, Food, and Diagnostics/Clinical partially offset by continued soft Chemical/Energy markets Analytical Laboratory End Markets Agilent Revenue by End Market (1) Q4'16 revenues: +6% y/y on core(2) basis Phar
Slide 8: Profitable Growth Plan
Agilent Profitable Growth Plan Recent Actions Delivering on “Agile Agilent” Initiatives • Multi-year program to increase efficiency and customer focus. • Operating Margin up year-over-year – 7th consecutive quarter. • Freezing U.S. defined benefit retirement plan. • Integration of Dako on Agilent
Slide 9: Strategy to Win
Agilent Strategy to Win Creating shareholder value Above Market Growth • Win enterprise lab-wide services & consumables - CrossLab • Accelerate bio-pharma penetration • Drive adoption of clinical genomics applications Aggressively expand operating margins • FY16 Operating Margin of 20.7%(2) expa
Slide 10: Q1'17 and FY17 Guidance and Forward-looking Considerations
Q1’17 and FY17 Guidance and Forward-looking Considerations Based on October 31, 2016 Exchange Rates FY17 FY17 Guidance FY16 Guidance at • Revenue: $4.35B - $4.37B: growth at mid-point 4.3% core(4), 3.7% (2) mid-point Actual reported (1) (0% M&A, -0.6% FX) (1)(2) • Operating Margin: 21.0% at mid-poin